

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PuraPharm

PURAPHARM CORPORATION LIMITED

培力控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1498)

POSITIVE PROFIT ALERT

This announcement is made by PuraPharm Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2018 and other information currently available to the Board, it is expected that both of the Group’s revenue and profit for the six months period ended 30 June 2018 will record an increase of more than 30%, as compared with the overall revenue and profit of the Group during the corresponding period in 2017.

The increase in revenue was mainly attributable to:

- (i) an increase in sales of the Group’s China Concentrated Chinese Medicine Granules (“**CCMG**”) segment resulted from the increase in sales quantity to the Group’s distributors. During the six month period ended 30 June 2018, the Group continued to devote more selling and distribution expenses to strengthen the promotion of the Group’s products and brands in China, as a result, more new customers were developed and the sales to the Group’s existing customers continued to growth.
- (ii) the results of the newly acquired subsidiaries in 2017 were fully consolidated in the Group’s result for the six month period ended 30 June 2018, in which only a few months results since the completion of the acquisitions were consolidated in the Group’s result for the during the corresponding period in 2017.

The increase in profit was primarily attributable to (i) an increase in fair value gain on the Group's biological assets as compared to the corresponding period ended 30 June 2017 based on a valuation of the biological assets as of 30 June 2018, (ii) an increase in the profit contribution from China CCMG segment as compared to the corresponding period ended 30 June 2017, and (iii) profit contributed by the newly acquired subsidiaries in 2017.

The Company is still in the process of finalising the interim results of the Group for the six months ended 30 June 2018. The information contained in this announcement is only based on the preliminary assessment by the Board with reference to the information currently available including the unaudited consolidated management accounts of the Group, which have not been reviewed or audited by the Company's auditor or the audit committee of the Company and are subject to adjustment. The actual interim results of the Group for the six months ended 30 June 2018 may be different from what is disclosed in this announcement. Shareholders of the Company and potential investors are advised to read carefully the interim results announcement of the Company for the six months ended 30 June 2018, which is expected to be published by the end of August 2018 in accordance with the Listing Rules.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman

Hong Kong, 13 August 2018

As at the date of this announcement, the executive directors of the Company are Mr. Chan Yu Ling, Abraham, Dr. Tsoi Kam Biu, Alvin, Mr. Chan Kin Man, Eddie, and Ms. Man Yee Wai, Viola; and the independent non-executive directors of the Company are Dr. Chan Kin Keung, Eugene, Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.